The effect of ondansetron on reduction of etomidate-induced myoclonic movements

The effect of ondansetron on reduction of etomidate-induced myoclonic movements in patients with ophthalmic surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190510043545N2

Enrollment

Registered

2021-10-02

Start date

2021-10-07

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

etomidate-induced myoclonic movements. Myoclonus

Interventions

Intervention 1: The ondansetron group received 4 mg (IV) (group O) before Etomidate and received the drug as a prodrug 180 seconds before induction with Etomidate at a dose of 0.3 mg / kg.This drug is

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults (over 18 years old) ASA??-? who are candidates for elective ophthalmic surgery. And consent to participate in the study.

Exclusion criteria

Exclusion criteria: Patients with adrenal dysfunction Drug allergy Mental disorders Neuromuscular disease Seizures Electrolyte disorders Surgery with a high risk of nausea and vomiting such as strabismus

Design outcomes

Primary

Measure	Time frame
Intensity of myoclonus. Timepoint: The occurrence and severity of myoclonus are controlled from the time of injection to 90 seconds after atomiditis injection. Method of measurement: myoclonic movements score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohamad Alipour

Mashhad University of Medical Sciences

sjvdpurafzali@yahoo.com+98 51 3840 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026